New triple inhaler could simplify asthma care for teens

NCT ID NCT05776927

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This study tests a new once-daily inhaler called QVM149, which combines three medicines (indacaterol, glycopyrronium, and mometasone furoate) to control asthma. It will enroll 304 teenagers aged 12 to 17 and compare the new inhaler to a standard twice-daily treatment (salmeterol/fluticasone). The main goal is to see if QVM149 improves lung function over 26 weeks, with follow-up for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QVM149 (a combination of indacaterol, glycopyrronium, and mometasone furoate) delivered via inhaler
What this could lead to: If successful, this could offer a more effective once-daily inhaler option for teenagers with asthma, potentially improving lung function and symptom control compared to current twice-daily treatments.
What could go wrong: This is a Phase 3 trial, so it's further along, but it's still testing a new combination. It may not prove superior to existing treatments, and side effects like throat irritation or increased heart rate are possible. Results may not apply to all asthma severities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Krugersdorp, Gauteng, 1739, South Africa
Novartis Investigative Site
RECRUITING

Lenasia, Gauteng, 1827, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.